Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Pleiotrophin Stimulates Expansion of Cord Blood Stem Cell Cultures

By LabMedica International staff writers
Posted on 29 Mar 2010
Researchers have identified a growth factor that stimulates the expansion of stem cell cultures from cord blood and that may make populations of such cells useful for treatment of patients lacking the cellular machinery --due to chemotherapy or radiation treatment, for example--for production of blood cells.

Investigators at Duke University (Durham, NC, USA) worked with a growth factor called pleiotrophin. More...
This growth factor is known by several other names including Neurite Growth-promoting Factor 1 (NEGF1), Heparin Affin Regulatory Peptide (HARP), or Heparin Binding Growth associated molecule (HB-GAM). It is an 18-kDa molecular weight growth factor that has a high affinity for heparin. During embryonic and early postnatal development, pleiotrophin is expressed in the central and peripheral nervous system and also in several nonneural tissues, notably lung, kidney, gut, and bone.

In the current study, the investigators treated mouse bone marrow hematopoietic stem cells (HSCs) with pleiotrophin. They also treated cultures of human cord blood cells with the growth factor as well as administrating it in a systemic fashion to irradiated mice.

Results published in the March 21, 2010, online edition of the journal Nature Medicine revealed that pleiotrophin stimulated a ten-fold expansion of mouse bone marrow stem cells. Treatment of human cord blood cultures resulted in substantially increased severe combined immunodeficient (SCID)-repopulating cell counts as compared to input and cytokine-treated cultures. Systemic administration of pleiotrophin to irradiated mice caused a pronounced expansion of bone marrow stem and progenitor cells, indicating that pleiotrophin was a regenerative growth factor for HSCs. So far, there has been no evidence that use of pleiotrophin could trigger formation of cancer cells, since the investigators have not seen any evidence of cancer in mice up to six months after treatment with pleiotrophin.

"These results confirmed that pleiotrophin induces stem cell regeneration following injury,” said senior author Dr. John Chute, professor of cell biology at Duke University. "Perhaps more importantly, systemic treatment with pleiotrophin may have the potential to accelerate recovery of the blood and immune system in patients undergoing chemotherapy or radiotherapy. At this point, any progress we can make that helps us better understand which biological pathways are activated in stem cells in response to pleiotrophin will help move the discovery forward.”

Related Links:

Duke University



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.